24/7 Market News Snapshot 21 April, 2025 – TransCode Therapeutics, Inc. Common Stock (NASDAQ:RNAZ)

April 21, 2025

DENVER, Colo., 21 April, 2025 (www.247marketnews.com) – (NASDAQ:RNAZ) are discussed in this article.
TransCode Therapeutics, Inc. has exhibited remarkable growth in recent trading sessions, with shares climbing from an opening price of $0.278 to a notable $0.296, representing a substantial increase of 8.62%. The trading volume exceeded 13.25 million shares, reflecting heightened investor engagement and bolstering anticipations for continued upward movement. This surge has successfully surpassed critical resistance levels, indicating a positive trajectory for the stock. Traders are advised to monitor for further volume increases and to pay attention to momentum indicators that may confirm the stock’s resilience. A sustained close above the $0.30 mark could potentially pave the way for additional gains, while a decline below the day’s opening price might suggest a possible correction.

In a parallel development, TransCode has announced the postponement of its Special Meeting, originally slated for April 21, 2025. The gathering has been rescheduled for May 2, 2025, at 9:30 a.m. Eastern Time, transitioning to a virtual format to facilitate increased participation. This meeting will focus on crucial proposals, most notably Proposal One, which seeks shareholder approval for a reverse stock split of the Company’s common stock. The intended ratio is likely to fall between one-for-ten and one-for-forty, allowing the Board of Directors discretion within this range. Proposal Two will address the potential for further adjournments if necessary to ensure comprehensive shareholder feedback.

TransCode encourages all eligible shareholders to cast their votes by the deadline of May 1, 2025, at 11:59 p.m. Eastern Time, to ensure their opinions are considered. Voting options include online, via phone, or during the virtual meeting, where shareholders will also have the opportunity to ask questions. Committed to revolutionizing cancer treatment through cutting-edge RNA therapeutics, TransCode continues to mark significant progress in the fight against metastatic disease.

Related news for (RNAZ)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.